Legal News

Of mice and patents—Kymab beats Regeneron for insufficiency

Of mice and patents—Kymab beats Regeneron for insufficiency
Published on: 11 February 2016
Published by: LexisPSL
  • Of mice and patents—Kymab beats Regeneron for insufficiency
  • Original news
  • What is the commercial and legal background to this judgment?
  • What were the legal aspects of the insufficiency attack?
  • What was said about product-by-process ‘obtainable by’ claims?
  • What was the finding on infringement?
  • What was the nature and outcome of the cross-anticipation attack involving priority?
  • Are there any points for lawyers and their clients to take away?
  • Technical Primers
  • Submission on draft judgments
  • More...

Article summary

IP & IT analysis: What does this case tell us about insufficiency? Dr Beatriz San Martin, partner at Fieldfisher, draws out key points and lessons from Regeneron Pharmaceuticals Inc v Kymab. or take a trial to read the full analysis.

Popular documents